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Abstract Cerebral microdialysis is a sampling technique
which offers much potential for understanding inflammatory
pathophysiology following traumatic brain injury (TBI). At
present, the recovery of cytokines via microdialysis in clinical
studies is not straightforward primarily due to their size, steric
properties and low concentrations. Heparin and heparin-
coated microspheres have previously shown promise as
cytokine-binding agents for enhanced microdialysis sampling
in animal models (Duo and Stenken in Anal Bioanal Chem
399(2):773–82, 2011; Anal Bioanal Chem 399(2):783–93,
2011). However, there are several factors limiting application
for microdialysis in patients. The aim of this study was to
produce heparin-coated gold nanoparticles as cytokine capture
agents for enhanced microdialysis sampling, potentially appli-
cable to a clinical setting. Gold nanoparticles (AuNP) were
chemically conjugated to heparin via a bifunctional polyeth-
ylene glycol (PEG) linker. The heparin-AuNP (AuNP-Hep)
were characterised, demonstrating the successful addition of
heparin to the gold surface. The performance of the AuNP-
Hep during in vitro testing was compared both to current
methodology (Helmy et al. in J Neurotrauma 26(4):549–61,
2009) and to the heparin-coated microspheres developed by
Duo and Stenken (Anal Bioanal Chem 399(2):773–82, 2011;
Anal Bioanal Chem 399(2):783–93, 2011). The AuNP-Hep
yielded a higher recovery of cytokines compared to current
methodology and heparin-coated microspheres, during
in vitro testing designed to mimic the human environment
and the intensive care unit. In this study, AuNP-Hep were
developed for enhanced microdialysis sampling of cytokines,
potentially applicable in a clinical setting. Based on the suc-
cess of the AuNP-Hep in vitro, the proposed method offers an
alternative to the use of current protocols that rely on a blood
product (albumin) for microdialysis sampling of cytokines in
patients.
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Introduction
Cerebral microdialysis is a monitoring technique used in trau-
matic brain injury (TBI) patients which has both clinical and
research applications. Microdialysis enables sampling from
the extracellular space in vivo, thereby providing a unique
opportunity to study underlying inflammatory processes that
occur in the brain after traumatic injury, as well as potentially
identifying therapeutic targets. Microdialysis sampling is
based on the free diffusion of analytes across a semi-
permeable membrane with a nominal molecular weight cut-
off (MWCO). The membrane is attached to the inlet and outlet
tubing through which perfusion fluid (PF) is slowly passed
and collected [1]. Cytokines are key mediators in the inflam-
matory processes which can occur following TBI [2, 3].
Cerebral microdialysis has previously been applied for the
Electronic supplementary material The online version of this article
(doi:10.1007/s00216-017-0447-y) contains supplementary material,
which is available to authorized users.
* Susan Giorgi-Coll
sv377@cam.ac.uk
1 Division of Neurosurgery, Department of Clinical Neurosciences,
University of Cambridge, Box 167, Cambridge Biomedical Campus,
Cambridge CB2 0QQ, UK
2 Wolfson Brain Imaging Centre, Department of Clinical
Neurosciences, University of Cambridge, Box 65, Cambridge
Biomedical Campus, Cambridge CB2 0QQ, UK
Anal Bioanal Chem
DOI 10.1007/s00216-017-0447-y
sampling of cytokines from TBI patients 2–8 days after injury
[4, 5].
The recovery of proteins such as cytokines via microdial-
ysis sampling poses a significant challenge. Proteins are diffi-
cult to collect due to their low diffusion coefficients across the
microdialysis membrane and their typically low concentra-
tions (pg/mL) in the brain [1]. PF containing affinity-based
trapping agents targeted to the protein of interest has been
applied to overcome this problem [1]. By binding the protein
within the microdialysis catheter, the trapping agent produces
an artificially low concentration in the PF, thereby driving
diffusion across the membrane [6]. Increased diffusion via
mass transport, together with a chemical reaction across the
membrane, causes more of the protein analyte to enter the
catheter and thereby improves recovery (Fig. 1). At present,
PF supplemented with human serum albumin (HSA) is the
gold standard for improving cytokine recovery during clinical
microdialysis [7]. However, the acquisition of blood products
such as HSA for clinical use is becoming increasingly difficult
in Europe due to licencing changes in pharmacy manufactur-
ing units. It is imperative for the continued clinical use of
microdialysis that alternative strategies for improving cyto-
kine recovery which do not require blood products, such as
those using affinity-based trapping agents, are developed.
Heparin has been applied as one such cytokine capture
agent during in vitro microdialysis [6]. Heparin, a highly polar
and linear polysaccharide belonging to a family of glycosami-
noglycan (GAG), is known to bind a range of cytokines and
chemokines with micromolar to nanomolar affinity [1]. The
main advantage of using heparin over antibodies as a capture
agent is the faster dissociation rate associated with heparin-
cytokine interactions, which allows cytokines to be removed
after sampling for detection. Furthermore, heparin is inexpen-
sive, widely available and chemically more stable than anti-
bodies [8]. Wang and Stenken reported a 2–5-fold increase in
the relative recovery (RR) of five cytokines, namely IL-4, IL-
6, IL-7, MCP-1 and TNF-α, using microdialysis perfusion
fluid supplemented with 0.1 μM heparin [6]. At this concen-
tration, a low loss of heparin across the 100-kDa MWCO
microdialysis membrane (2.7 ± 0.9%, n = 3) was reported
[6]. This is thought to be due to its rigid linear polymeric
structure and large hydrodynamic radius, both of which limit
diffusion across the catheter membrane.
Due to safety concerns regarding free heparin, Stenken and
colleagues also developed and applied heparin-coated micro-
spheres (Hep-beads) for enhancing cytokine recovery during
microdialysis [1, 9]. In vitro studies using the Hep-beads
showed that the concentration of Hep-beads did not change
during sampling, suggesting that no Hep-beads were able to
pass through the microdialysis membrane [8]. In vivo results
in rats showed that the same concentration of heparin elicited
the same improvement of RR, whether free or immobilised
onto a bead surface, thereby demonstrating the potential of
Hep-beads as a viable alternative to free heparin [8].
However, the size of the beads means that they are liable to
settle in the delivery syringe during microdialysis sampling
and therefore require a rotating platform in order to work,
which is not practical in a clinical setting.
In this study, AuNP were selected as an alternative particle
for their biocompatibility, stability in aqueous solutions,
unique optical properties and low cost. The small size of
AuNP enables them to remain in suspension after
Fig. 1 A schematic overview
demonstrating the recovery of
cytokines in vitro, by a standard
microdialysis, and b enhanced
microdialysis using heparin-
coated particles
Giorgi-Coll S. et al.
functionalisation, and therefore, they would not require rota-
tion during microdialysis sampling as is necessary with the
Hep-beads. In addition, the unique surface plasmon resonance
of AuNP provides opportunities for the future development of
optical tests for cytokines of interest. Heparin-functionalised
gold nanoparticles (AuNP-Hep) were synthesised,
characterised and tested in vitro for their capability to enhance
recovery of cytokines during microdialysis in a clinical set-
ting. Heparin-coated microspheres were also prepared (as de-
scribed by Duo and Stenken [8, 9]) and tested in vitro. The
two heparin-particle types were compared to the current meth-
od (PF supplemented with HSA) in an in vitro setting that
closely approximates the clinical environment, to ascertain
whether either will be suitable for use in human patients. As
yet, no study has tested heparin-particles in this context, and it
is a necessary step before implementing it in human patients.
Materials and methods
Materials
All reagents were of analytical grade, purchased from Sigma-
Aldrich (Poole, Dorset, UK) and used as received unless oth-
erwise stated. Sodium phosphate dibasic, sodium chloride,
sodium dodecyl sulphate (SDS) and potassium chloride were
purchased from BDH laboratory supplies (Poole, UK).
Millipore Amicon ultra 0.5 mL centrifuge filter tubes
(10,000 and 100,000 MWCO) were purchased from Thermo
Fisher (Loughborough, UK). Bangs Laboratories polybead
amino microspheres (6.0 μm o.d., 8.26 × 107 beads/mL in
deionised water containing 0.1% SDS) were purchased from
Polysciences Europe GmbH (Eppelheim, Germany). Kova
Glasstic microscope slides (10 grids) were purchased from
VWR (Lutterworth, UK). Holey carbon film 300 mesh copper
grids were purchased from Agar Scientific (Stansted, UK).
CMA71 brain microdialysis catheters (100 kDa nominal
MWCO, 10 mm polyarylethersulfone [PAES] membrane
length), microdialysis vials, CMA106 microdialysis pumps
and corresponding batteries and syringes were purchased from
M Dialysis AB (Stockholm, Sweden). ProcartaPlex human
cytokine and chemokine (panel 1A) 34-plex bead assays and
human cytokine and chemokine standard mixes A and B were
purchased from Affymetrix eBioscience (Hatfield, UK).
All centrifugation steps were performed using a Hettich
Universal 320R centrifuge. In vitro sampling with heparin
beads was performed using a Grant-Bio PS-3D Sunflower
mini-shaker. Citrate AuNP synthesis and in vitro microdialy-
sis sampling with AuNP-heparin were performed using a
VWR advanced hotplate magnetic stirrer with temperature
probe. Catheters were held in place during in vitro sampling
using a triple lumen cranial access device (Technicam,
Newton Abbott, UK). UV-Vis absorption spectra (200–
700 nm) were recorded on a Hitachi U-3000 spectrophotom-
eter at room temperature. Quartz cuvettes with a 1-cm path
length were used. Azure A assay absorbance intensity read-
ings were recorded using an Anthos Multiread 400 plate read-
er. Transmission electron microscope (TEM) images were ob-
tained using a FEI Tecnai F20 FEGTEM operating at 200 kV.
Luminex multiplex assays were analysed using a Luminex
200 analyser (Luminex Corporation, Austin, TX, USA) oper-
ating with Luminex xPonent software. Wash steps were per-
formed using either a BioTek ELx405 automated microplate
washer (Winooski, VT, USA) or a ProcartaPlex handheld
magnetic plate holder.
Buffers and solutions
All high-purity deionised water (dH2O) used was of HPLC
grade (18.2 MΩ cm, Millipore Direct Q5 UV water purifica-
tion system with LC-Pak polisher). Microdialysis PF was
made in-house (147 mM NaCl, 2.7 mM KCl, 1.2 mM
CaCl2, 0.85 mMMgCl2; pH ∼ 6.0), to the same specifications
as the manufactured PF used for brain microdialysis in pa-
tients in our neurocritical care unit (NCCU). 2-(N-
morpholino)methanesulfonic acid buffer (MES buffer) was
made at 50mM, pH 5.5 with 0.01% (w/v) SDS. HEPES buffer
was made at 50mM, with 100mMNaCl (pH 7.4). Phosphate-
buffered saline (PBS) was made to the concentrations and pH
values specified.
AuNP synthesis and characterisation
Sixteen-nanometer citrate-stabilised gold nanoparticles
(cAuNP) were synthesised according to the method of
Turkevich et al. [10]. The concentration of AuNP was calcu-
lated based on the extinction at 520 nm and the extinction
coefficient 2.4 × 108 M−1 cm−1 [11]. TEM was used to char-
acterise the size and morphology of the AuNP; 10 μL of the
AuNP in solution was placed onto a holey carbon film 300
mesh copper grid. Excess solvent was removed from the sam-
ple by touching the side of the grid with adsorbent tissue
paper. The grid was dried overnight at room temperature be-
fore analysis by TEM, as previously described. Measurement
of the cAuNP was performed using ImageJ software.
Preparation of the heparin-AuNP
Heparin-AuNP were prepared using a bifunctional PEG link-
er, with both a thiol functional group for tethering onto the
surface of the AuNP, and a terminal amine which can be
coupled onto the heparin. The PEG linker was used to increase
the size of the AuNP, as well as to impart additional stability
under biological conditions [12, 13]. The PEG was self-
assembled onto the AuNP as follows: a w/v ratio of 1 PEG:1
AuNP was self-assembled by adding 5 mg of HS-
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poly(ethylene glycol)-NH2 (averageMW2000; PEG) to 5 mL
of cAuNP, prepared as described above. The mixture was
gently stirred for 12 h at room temperature. Unbound PEG
was removed by centrifuge filtration (100,000 MWCO;
15min, 8000×g), after which the AuNP-PEGwere resuspend-
ed in 2.5 mL MES buffer with SDS. Coupling of the heparin
to the AuNP-PEG was performed using sulfo-NHS/EDC
chemistry, as previously applied by Benoit et al., among
others [14, 15]; 25 μL of an EDC/sulfo-NHS solution
(0.1 M EDC and 0.1 M sulfo-NHS in dH2O) was added to
100 μL of heparin (10 mg/mL in MES buffer with SDS). The
solution was reacted for 15 min at room temperature with
gentle stirring, after which 2.5 mL of the AuNP-PEG (pre-
pared as above) was added. The solution was vortex mixed
before being gently stirred for 2 h at room temperature. After
incubation, the AuNP-heparin (AuNP-Hep) were washed suc-
cessively with MES buffer with SDS and 100 mM ethanol-
amine, to quench unreacted carboxyl groups;MES buffer with
SDS; and finally PF with 0.05% (w/v) sodium azide and 1 mg/
mL human serum albumin (HSA).Washingwas performed by
centrifuge filtration (100,000MWCO; 15min, 8000×g). After
the final wash, the AuNP-Hep were resuspended in PF with
0.05% (w/v) sodium azide and 1 mg/mL HSA. The AuNP-
Hep were stored at 4 °C.
Once purified, modification of the AuNP surface was de-
termined by UV-Vis spectrophotometry at ca. 520 nm. The
amount of immobilised heparin was detected using the hepa-
rin dye Azure A [16], as per the method of Bai et al. [17]. A
standard curve comprising heparin concentrations between
0.195 and 50 μM was prepared in HEPES buffer. For the
assay, 180 μL of Azure A dye (150 μM, in HEPES buffer)
was mixed with 20 μL of standard or sample in a 96-well
microplate, before being incubated for 30 min at room tem-
perature in the dark. The absorption of the samples was then
measured by a plate reader at 620 nm.
Cytokine binding
The cytokine-binding capability of the AuNP-Hep was deter-
mined by incubation in PF containing 34 human cytokines;
AuNP-PEG treated in the same way were used as a negative
control. Unbound cytokines were removed by washing.
Bound cytokines were removed from the heparin using a dis-
sociation step in 20% (v/v) acetonitrile as described by Duo
and Stenken [8]. The concentration of cytokine bound to the
AuNP-Hep was then determined by multiplex immunoassay
and compared with the control. The storage buffer was first
removed from the AuNP-PEG and AuNP-Hep (ca. 3.5 nM;
1 mL of each) by centrifuge filtration (100,000 MWCO;
15 min, 8000×g). The AuNP were then resuspended in an
external solution (ES) comprising PF with 0.05% (w/v) sodi-
um azide, 1 mg/mL HSA and 34 human cytokines, prepared
as follows. The cytokine standards, received as a set of two
lyophilised powders (A and B) containing a mixture of differ-
ent cytokines, were resuspended in accordance with the man-
ufacturers’ instructions and subsequently diluted to 1:100 in
PF with 0.05% (w/v) sodium azide and 1 mg/mL HSA.
Following this dilution, the final cytokine concentrations used
in the experiments are as listed in Table 1. A 2-h incubation
was performed at room temperature with gentle shaking
(120 rpm). Unbound cytokines were removed by washing
three times with PF with 0.05% (w/v) sodium azide and
1 mg/mL HSA; wash steps were performed by centrifuge
filtration (100,000 MWCO; 15 min, 8000×g). A fourth and
Table 1 Concentrations of cytokine standards used during cytokine
binding and in vitro sampling experiments. Standards were diluted to
concentrations that reflect those found in the brain’s extracellular fluid
by Hutchinson et al. [3], assuming a 20% relative recovery (RR) [7]
Cytokine/chemokine Concentration (pg/mL)
Eotaxin 25
GM-CSF 543
GRO-alpha 95
IFN-alpha 22.5
IFN-gamma 306
IL-1alpha 22
IL-1beta 84
IL-1ra 1438
IL-2 175
IL-4 463
IL-5 263
IL-6 334
IL-7 20
IL-8 89
IL-9 315
IL-10 92
IL-12p70 262
IL-13 88
IL-15 125
IL-17alpha 74
IL-18 280
IL-21 319
IL-22 1082
IL-23 559
IL-27 1002
IL-31 546
IP-10 88
MCP-1 65
MIP-1alpha 64
MIP-1beta 135
RANTES 36
SDF-1alpha 398
TNF-alpha 267
TNF-beta 238
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final wash was performed in PF, after which the cytokines
were removed from the surface of the Hep-beads and AuNP-
Hep using a dissociation step modified from Duo and Stenken
[9]. The AuNP-PEG and AuNP-Hep were resuspended in PF
containing 10% (v/v) acetonitrile and incubated for 12–14 h at
4 °C. After this dissociation step, the AuNP-PEG and AuNP-
Hep were centrifuge filtered (100,000 MWCO; 15 min,
8000×g), and the supernatant containing the cytokines
retained. Samples were stored at −75 °C for up to 2 months
prior to analysis.
Preparation of the heparin beads
Conjugation of heparin onto Bangs’ amine-functionalised
polymer microspheres was achieved using a modified version
of the method described by Duo and Stenken [8, 9]. The
polymer beads (100 μL of stock suspension, 8.26 × 107
beads/mL) were washed three times with 400 μL of PBS
(0.2 M, pH 7.0) by centrifuge filtration (10,000 MWCO;
10 min, 14,000×g). Following centrifugation, the micro-
spheres were resuspended in 500 μL of 6 mg/mL solution of
heparin in PBS (0.2M, pH 7.0). The beads were diluted to 1:2
in 6 mg/mL sodium cyanoborohydride, and the solution was
incubated for 48 h on a microplate shaker (1000 rpm, at room
temperature). After incubation, the microspheres were washed
three times with 400 μL of sodium acetate buffer (0.2 M, pH
7.0) by centrifuge filtration (100,000 MWCO; 10 min,
14,000×g). After washing, the microspheres were resuspend-
ed in 1 mL sodium acetate buffer (0.2 M, pH 7.0) containing
1 mg/mL SDS; 0.5 mL acetic anhydride was added dropwise
to the suspension, and the solution was incubated at room
temperature for 1 h to deactivate any unbound amine groups.
After incubation, the microspheres were washed successively
with 300 μL sodium acetate buffer (0.2M, pH 7.0) with 1 mg/
mL SDS, dH2O, and finally in 400 μL of 10 mM PBS (pH
7.4) with 0.05% (w/v) sodium azide. The microspheres were
then resuspended in 100 μL of PBS (10 mM, pH 7.4) with
0.05% (w /v ) sodium azide and counted using a
haemocytometer. The heparin beads were stored at 4 °C.
In vitro microdialysis sampling
Prior to microdialysis sampling, 1.5 mL of AuNP-PEG was
washed by centrifuge filtration (100,000 MWCO; 15 min,
8000×g) to remove the buffer and resuspended in 1.5 mL of
PF with 0.05% (w/v) sodium azide and 1 mg/mL HSA. The
AuNP-Hep were prepared as previously described. The Hep-
beads were prepared as follows: a 4 × 106 beads/mL concen-
tration was achieved by diluting 176.5 μL of the beads (as
calculated for the final 3 mL volume) in 823.5 μL of PF.
The beads were divided into two equal parts, washed by cen-
trifuge filtration (10,000MWCO; 10min, 14,000×g) and then
resuspended in 1.5 mL of PF with 0.05% (w/v) sodium azide
and either 35 or 1 mg/mL HSA. The solutions were then
loaded into syringes and CMA107 microdialysis perfusion
pumps.
In vitro microdialysis sampling was performed in an ES
containing 34 human cytokines. The ES was prepared as pre-
viously described for the cytokine-binding experiments;
25 mL of ES was made up in a 50-mL centrifuge tube. The
tube was suspended using a clamp stand in either a thermo-
statically controlled water bath (for the Hep-bead sampling) or
glycerol bath (for the AuNP-Hep sampling) set to 37 °C. Very
gentle agitation of the external solution was applied using a
magnetic stirrer. Two or three CMA71 brain microdialysis
catheters were placed into the external solution through a tri-
ple bolt cranial access device, which was secured within the
centrifuge tube using self-adhesive plastic film. Each catheter
was perfused at 0.3 μL/min using CMA107 pumps, with sy-
ringes loaded with ca. 1.5 mL of PF, prepared as described
above. The different types of PF used in this study are
summarised in Table 2. Once connected, pumps were placed
onto a rotating shaker platform set at low speed. The
microdialysate samples were collected in microdialysis vials
at the end of each catheter. Pumps and collection vials were
kept at the same height on either side of the water/glycerol
bath, to nullify any hydrostatic pressure differences. Sampling
was performed for 48 h in total; the microdialysis vials were
changed every 12 h. Samples were stored at 4 °C until the
dissociation step was carried out (within 24 h of sampling).
A schematic of the in vitro sampling setup is shown in Fig. 2.
After sampling, the microdialysate samples were diluted to a
1:2 concentration in PF supplemented with 20% (v/v) aceto-
nitrile and incubated at 4 °C for 10–12 h to remove the cyto-
kines from the surface of the Hep-beads and AuNP-Hep. After
the dissociation step, the AuNP-PEG and AuNP-Hep were
removed by centrifuge filtration (100,000 MWCO; 15 min,
8000×g), and the supernatant containing the cytokines
retained. Samples were stored at −75 °C for up to 1 month
prior to analysis.
Sample analysis
Quantitative analysis of cytokine concentration was per-
formed using an eBiosciences ProcartaPlex 34-plex human
cytokine immunoassay kit. The samples were thawed and
gently vortex mixed before analysing. Twenty-five microliters
of the sample was used per well; all samples were analysed in
duplicate. The assay was performed as per the manufacturers’
instructions. Wash steps were carried out using either an au-
tomated plate washer (for the Hep-bead analysis) or a hand-
held magnetic plate holder. All assays were analysed on a
Luminex 200 platform. The RR was determined based on
the average of the duplicate measurements for each sample.
Data analysis was performed using xPonent and Origin
software.
AuNP-Hep for enhanced microdialysis sampling
Results and discussion
AuNP synthesis and characterisation
AuNP were synthesised according to the citrate reduction
method of Turkevich et al., as described in the BMaterials and
methods^ section [18]. Heparin was added to the surface of the
AuNP via a two-step procedure, in which a PEG linker was
first bound to the AuNP followed by the subsequent addition of
the heparin. Unbound heparin was removed by three wash
steps, the supernatant of which was analysed by UV-Vis spec-
trophotometry (Fig. 3a). Removal of the unbound heparin is
shown by the decreasing peak at its absorbance maximum at
ca. 275 nm [19]. This result was verified by additional analysis
of the wash supernatants by Azure A assay. The results showed
decreasing concentrations of heparin after each wash step, with
no heparin detected in the final wash, in agreement with the
UV-Vis results (data not shown). cAuNP absorb light in the
visible spectrum with a maximum at ca. 520 nm, yielding an
extinction spectrum as shown in Fig. 3b. The concentration of
the newly synthesised cAuNP shown in Fig. 3b was deter-
mined to be 3.37 nM using the extinction coefficient
2.4 × 108 M−1 cm−1 [11, 20–22]. The binding of PEG and
subsequently the heparin to the surface of the AuNP is demon-
strated by an increase in peak extinction of approximately 1–
2 nm per addition, as shown in Fig. 3b. This shift to the red
region of the spectrum is indicative of modification of the sur-
face of the AuNP, resulting in a size increase which is reflected
by increased absorption. The results shown confirm the suc-
cessful addition of PEG and heparin to the particle surface.
TEM was used to visualise the cAuNP and AuNP-Hep
(shown in panels a and b of Fig. 4, respectively). The average
diameter of the cAuNP was measured from the TEM images;
results are shown in Fig. 4c. The calculated average diameter
of the cAuNP was 15.0 ± 1.3 nm (n = 100). The presence of
heparin on the surface of the AuNP-Hep was confirmed by
Azure A assay. The assay showed that heparin was present on
the AuNP-Hep and absent on the AuNP-PEG negative con-
trol. A ratio of 108 heparin molecules per AuNP was estimat-
ed based on the quantity of heparin determined by Azure A
assay.
Cytokine binding
The cytokine-binding capacity of the AuNP-Hep was deter-
mined by incubation in a solution containing 34 human cyto-
kines, followed by four wash steps, decoupling and detection.
Identical treatment of AuNP-PEG served as a negative con-
trol. Figure 5 shows the concentration of different cytokines
obtained using the AuNP-Hep versus the control. Additional
data showing the recovery of cytokines from the sampling
solution, expressed as relative recovery (in %), is provided
in the Electronic supplementary material (ESM) Table S1.
Overall, application of the AuNP-Hep resulted in enhanced
cytokine binding, as shown by the higher concentrations of
all 34 cytokines decoupled from the AuNP-Hep when
Table 2 A summary of the different types of PF compared during this study. The estimated average perfusion fluid concentrations of Hep-beads and
AuNP-Hep used were 44.0 × 105 beads/mL and 3.5 nM, respectively
Pump 1 Pump 2 Pump 3
Hep-beads
Repeat 1 PF with 1 mg/mL HSA Hep-beads in PF with 35 mg/mL HSA Hep-beads in PF with 1 mg/mL HSA
Repeat 2 PF with 1 mg/mL HSA Hep-beads in PF with 35 mg/mL HSA Hep-beads in PF with 1 mg/mL HSA
AuNP-Hep
Repeat 1 PF with 1 mg/mL HSA AuNP-Hep in PF with 1 mg/mL HSA AuNP-PEG in PF with 1 mg/mL HSA
Repeat 2 PF with 1 mg/mL HSA AuNP-Hep in PF with 1 mg/mL HSA –
Fig. 2 Diagram of the experimental setup. a Three CMA microdialysis
pumps with various perfusion fluids (as described in Table 2). b Catheter
setup via triple bolt to sample external solution (ES) in 37 °C water/
glycerol bath. c Collection vial. d Magnified schematic of microdialysis
catheter tip, demonstrating direction of perfusate flow and diffusion
across the outer catheter membrane
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compared with the PEG control. However, no significant dif-
ferences were seen in relative recovery when comparing the
AuNP-Hep with the control. This was due to the presence of
cytokines in the control samples, possibly due to steric prop-
erties in the PEG coating.
In vitro microdialysis sampling
The cytokine-binding enhancement of the AuNP-Hep during
microdialysis sampling was determined using an in vitro sam-
pling setup designed to resemble microdialysis monitoring in
TBI patients in our NCCU. The in vitro experiments were thus
carried out using the same microdialysis catheters (100 K
MWCO), pumps, flow rate (0.3 μL/min), collection vials
and PF composition as used clinically. Sampling was per-
formed at 37 °C, using three probes placed in a mixed standard
solution of 34 human cytokines under gentle agitation, diluted
to concentrations representative of those previously detected
in brain extracellular fluid and assuming a 20% RR [3, 5]. The
probes were perfused with different test solutions as detailed
in the BMaterials and methods^ section. After sampling, a
decoupling step was performed on all perfusates to remove
any bound cytokines from the heparin on either the Hep-beads
or the Hep-AuNP. The resulting cytokine concentrations
Fig. 4 Characterisation of the
AuNP-Hep by TEM and Azure A
assay. TEM images of the citrate
AuNP and the AuNP-Hep are
shown in a and b, respectively. c
The average size of the AuNP
core, estimated from the TEM
images, was 15.0 ± 1.3 nm
(n = 100). d The concentration of
heparin on the surface of the
AuNP-Hep determined by Azure
A assay. The average of three
separate batches of AuNP-Hep,
analysed in triplicate, is shown.
AuNP-PEG were used as a nega-
tive control
Fig. 3 UV-Vis absorption and extinction spectra during AuNP-Hep syn-
thesis. aRemoval of unbound heparin from the AuNP, as indicated by the
decreasing absorption at approximately 275 nm (Amax heparin = ca.
275 nm) during washing. b Extinction spectra of cAuNP, showing the
Amax at ca. 520 nm. After the addition of PEG and then heparin to the
AuNP surface, the peak extinction increases by 1–2 nm per surface mod-
ification. The AuNP-PEG were concentrated by 2× after the addition of
the PEG linker
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sampled using the AuNP-Hep relative to the PF control are
shown in Fig. 6. As demonstrated, sampling using AuNP-Hep
resulted in a higher recovered concentration in the majority of
the 34 cytokines tested for. Only the IL-31 concentration was
lower when sampled by AuNP-Hep, although this varied be-
tween runs, and both the test and control solutions were at
considerably higher concentration and recovery rate compared
with the other cytokines in this study. The high concentration
of IL-31 in the cytokine standard mix is thought to reflect its
high concentration in vivo when present.
Further comparison showed non-linear inverse trends be-
tween the RR (%) and the apparent molecular weight for the
34 cytokines, when sampled using the PF with HSA (Fig. 7a)
and the AuNP-Hep (Fig. 7b). These inverse trends were sta-
tistically similar (Spearman’s r = −0.325 and −0.322,
p = 0.061 and 0.063, respectively). A plot of RR using
AuNP-Hep (y-axis) versus RR with PF using HSA (x-axis)
gave a statistically significant positive correlation (linear re-
gression, r = 0.966, p ≤ 0.001) (Fig. 7c). The gradient of the
line fitted was 1.595; therefore, an overall factor of 1.595
improvement in RR was afforded by the AuNP-Hep relative
to that achieved with PF with HSA.
Based on the improved cytokine recovery achieved by the
AuNP-Hep compared to the PF control, the performance of
the AuNP-Hep was then tested in vitro and compared with the
Hep-beads developed by Duo and Stenken [8, 9]. These Hep-
beads were developed using commercial amine-functionalised
polymeric microspheres (ca. 6.0 μm), with heparin bound
directly to the functionalised surface ligand [9]. In vitro stud-
ies performed by Duo and Stenken showed that Hep-beads
performed well in terms of binding specificity and stability
[9]. In vivo sampling of monocyte chemoattractant protein-1
(or CCL2) was performed using microdialysis probes im-
planted into the peritoneal cavity of rats. The test catheters
were perfused with fluid containing either Hep-beads or free
heparin at a flow rate of 1.0 μL/min [8]. In the present study,
the Hep-beads were prepared using a modified version of the
method described by Duo and Stenken, and in vitro microdi-
alysis sampling was performed alongside a PF control in the
same way as for the AuNP-Hep [8, 9]. It was hypothesised
that the AuNP-Hep would yield a similar RR to that of the
Hep-beads in vitro. A comparison between the average RR
(%) achieved using the AuNP-Hep versus the Hep-beads, rel-
ative to the PF control, is shown in Fig. 8. In vitro sampling
performed using the AuNP-Hep resulted in significantly im-
proved RR over a PF control when compared with the Hep-
beads (p ≤ 0.01; one-way ANOVA; significance for individual
cytokines is as shown in Fig. 8). The use of the AuNP-Hep
Fig. 5 Results of the cytokine-
binding test, wherein the AuNP-
Hep were incubated in a mixed
standard solution of the 34 human
cytokines. Unbound cytokines
were then removed by washing,
followed by decoupling of bound
cytokines and detection. The
concentration of the cytokines
bound to the AuNP-Hep, versus
the concentration bound to the
AuNP-PEG negative control, is
shown. All cytokines with con-
centrations of >5 pg/mL are
shown; the remaining data can be
found in ESM Table S2. The data
shown here represents the average
of three repeat experiments, per-
formed and analysed in duplicate
(error bars = SEM). No signifi-
cant difference was found be-
tween the AuNP-Hep and the
AuNP-PEG control concentra-
tions (p > 0.05; one-way ANOVA
and paired sample t test)
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improved recovery for all but one of the cytokines sampled
for, namely IL-31, which showed a decreased RR in line with
the results of previous experiments (as shown in Fig. 6).
Fifteen of the cytokines sampled for by AuNP-Hep had sig-
nificantly improved RR when compared with the Hep-beads
(p ≤ 0.05 or 0.01; paired sample t test). These results clearly
show the efficacy of the AuNP-Hep for enhancing cytokine
recovery during microdialysis in vitro, in a setting representa-
tive of clinical monitoring.
One of the problems associated with using Hep-beads for
enhancedmicrodialysis sampling is that the beads are prone to
settling. This was identified by Duo and Stenken, who used a
custom-made rotating shaker to keep the syringe pump in
motion during microdialysis, as well as varying the flow rate
between 0.5 and 1 μL/min (and higher) to encourage bead
movement [8]. During brain microdialysis performed in a
clinical setting, the catheter itself is secured during surgery,
and tape is sometimes used to hold the tubing in place on the
ward. Nevertheless, it is imperative to move the microdialysis
system as little as practically possible, to minimise risk to both
the fragile probe and the patient. The microdialysis pump and
collection vial are situated immediately beside the patient’s
head, generally resting on the pillow or bedding. In the clinical
setting, it is clearly not practical to use a rotating shaker, as this
would disturb the microdialysis setup and pose a general haz-
ard to critical care. Furthermore, microdialysis in our NCCU is
performed using pumps with a fixed flow rate of 0.3 μL/min,
so using a variable flow rate is not possible in this context. In
this in vitro study, a small 3D oscillating platform was
employed in an attempt to emulate the movement achieved
by the custom rotating shaker used by Duo and Stenken [8].
Even with this in place, we observed that the beads had settled
at the beginning of the 48-h sampling period. The perfusion
rate of the beads was significantly reduced from the original
concentration in the syringe, as shown in Table 3. Our average
bead recovery of ca. 3% was significantly lower than the ca.
93% achieved by Duo and Stenken, likely due to the de-
creased flow rate and different probe types used in this study
[8].
The poor perfusion and recovery of the Hep-beads in our
in vitro setting representative of clinical microdialysis empha-
sises the need for an alternative approach capable of remaining
suspended during sampling. Based on visual observations, the
AuNP-Hep used in this study appeared to remain in solution
during sampling based on the characteristic burgundy colour
of the PF in the syringe, tubing and sample vial. These obser-
vations were confirmed by UV-Vis analysis of the PF contain-
ing AuNP-Hep before (from the syringe) and after microdial-
ysis of the samples (in the samples prior to decoupling). The
concentration of the AuNP-Hep was marginally higher (ap-
proximately 2%) in the sample than what was originally in the
syringe, as shown by the slight increase in peak extinction at
Fig. 6 The concentrations of 34
human cytokines from in vitro
microdialysis sampling using
AuNP-Hep. Average
concentrations from 48 h worth of
sampling (at 12 h sample
intervals), from two repeat
experiments analysed in
duplicate, are shown. All
cytokines with concentrations of
>5 pg/mL are shown; the
remaining data can be found in
ESM Table S3. Error bars denote
SEM. No significant difference
was found between the AuNP-
Hep and the PF with HSA control
concentrations (p > 0.05; one-way
ANOVA and paired sample t test)
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Fig. 7 Relative recoveries (%) for the 34 cytokines versus apparentmolecular
weight, and a comparison between AuNP-Hep and perfusion fluid (PF) with
HSA. aRR%using PFwith HSAversus apparent molecular weight (kDa). b
RR%usingAuNP-Hep versus apparentmolecularweight (kDa). The original
RR (%) data can be found in the ESM (Table S4). Spearman r and p values are
shown in each scatterplot; the p values were not significant in both a and b. c
RR% for PFwithHSAversus RR%with AuNP-Hep; the slope for the linear
regression is 1.595 (p ≤ 0.001)
Fig. 8 The change in relative
recovery (RR %) of 34 human
cytokines relative to a PF control,
sampled by microdialysis in vitro;
a comparison between AuNP-
Hep and Hep-beads. The average
RR (%) relative to the PF with
HSA control was calculated from
48 h worth of sampling (at 12 h
sample intervals), from at least
two repeat experiments analysed
in duplicate. Error bars denote
SEM. Significant differences
were observed between individu-
al cytokines sampled using
AuNP-Hep versus Hep-beads
(paired sample t test) and between
the overall concentrations obtain-
ed using the two sampling
methods (one-way ANOVA).
Statistical significance is denoted
as follows: *p ≤ 0.05 and
**p ≤ 0.01
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ca. 520 nm (Fig. 9). This result confirmed that the perfusion
and recovery of the AuNP-Hep during microdialysis was im-
proved compared to the Hep-beads. The slight increase in
AuNP-Hep in the sample is thought to be due to the slight
evaporation of fluid from the collection vial during the 12-h
sampling periods.
Safety is a serious concern for the potential clinical utility of
microdialysis catheters with perfusion fluids containing heparin
and AuNP. Heparin is an anticoagulant with known effects in
the human body. Although AuNP are considered relatively
inert, their physiological behaviour remains poorly
characterised [23]. As such, both heparin and AuNP should
be used with caution in a clinical setting. In the context of this
work, it is therefore imperative to demonstrate that the AuNP-
Hep are retained within the catheter during in vitro microdial-
ysis sampling. Wang et al. have previously shown, during
in vitro microdialysis using PF supplemented with 0.1 μM
heparin, that the heparin passes through the microdialysis cath-
eter in only very small amounts (2.7 ± 0.9%, n = 3) [6]. When
in vitro sampling was performed using Hep-beads, Duo and
Stenken reported that no heparin could be detected in the ES
[8]. In this study, we tested for heparin and AuNP in the ES by
Azure A assay and UV-Vis, respectively. Neither heparin (re-
sults not shown) nor AuNP (Fig. 9) were detected in the ES
using the aforementioned detection methods. During one of the
AuNP-Hep in vitro sampling experiments, AuNP-PEG were
applied as a negative control (as the AuNP-PEG are stable
under physiological conditions but do not contain heparin) in
one of the three catheters used. The AuNP-PEG passed through
the catheter during this experiment, resulting in a subtle visible
colour change in the ES, and a small AuNP extinction peak at
approximately 520 nm when measured by UV-Vis (results not
shown). The slight peak in absorption reflected an AuNP con-
centration of 0.07 nM in the ES when sampling was performed
using an AuNP-PEG control. When the in vitro sampling was
repeated using two catheters perfused with AuNP-Hep and PF
control, respectively, no AuNP were visible in the ES. UV-Vis
analysis of this ES also did not yield a peak at ca. 520 nm, and
the concentration of AuNP in the ES was estimated at 0 nM
(Fig. 9). These results suggest that, while the AuNP-PEG could
pass through the catheter, the AuNP-Hep could not do so at the
concentration levels detectable by UV-Vis. Although further
analysis will be required to fully characterise the behaviour of
the AuNP-Hep in the microdialysis catheter, these preliminary
results suggest that the AuNP-Hep are retained within the cath-
eter during in vitro sampling. Based on these results, enhanced
microdialysis sampling of cytokines using AuNP-Hep is there-
fore a viable option for use in TBI patients.
Conclusions
Microdialysis sampling of proteins can be challenging due to
factors including their size and steric properties. Improving
recovery via enhanced microdialysis increases the chance of
detecting important extracellular changes in protein concen-
tration, in environments such as the brain. In this study, we
have shown that microdialysis sampling using AuNP-Hep
improved the recovery of 34 human cytokines in an in vitro
setting designed to represent clinical monitoring in NCCU
patients. This enhanced recovery, yielding an increase in the
final concentrations detected, could improve detection of cy-
tokines in microdialysates, particularly those at low concen-
trations. The use of the AuNP-Hep would provide a suitable
means of overcoming the practical constraints of applying the
Hep-beads in a clinical setting, namely avoiding the need to
rotate the pump during sampling to avoid the beads from
settling. In addition, the AuNP-Hep provide a means of en-
hancing cytokine recovery without using blood products such
as HSA that have been successfully used in the past [2, 5, 7],
but have now become difficult to obtain in preparations suit-
able for clinical microdialysis. Increasing licencing
Table 3 Hep-bead concentrations (beads/mL) before, during and after in vitro microdialysis. Values are mean ± SD of three separate experiments,
based on 10 readings of each bead amount using a haemocytometer
0 h (before) Syringe; microdialysate; 24 h Microdialysate; 48 h Syringe; 48 h (after)
PF2a 42.8 ± 4.9 × 105 1.0 ± 0.4 × 105 1.0 ± 0.4 × 105 51.5 ± 2.7 × 105
PF3a 45.4 ± 3.5 × 105 1.9 ± 0.5 × 105 1.9 ± 0.7 × 105 45.6 ± 3.5 × 105
a PF2 comprises Hep-beads in PF with 35 mg/mL HSA; PF3 comprises Hep-beads in PF with 1 mg/mL HSA
Fig. 9 Typical UV-Vis absorption spectra of the PF containing AuNP-
Hep before (from the syringe) and after (in the sample prior to
decoupling) in vitro microdialysis sampling, as well as the spectrum of
the external solution (ES) after microdialysis. The concentration of the
AuNP-Hep is reflected by the peak extinction at ca. 520 nm (AuNP-Hep
syringe = 4.3 nM, AuNP-Hep sample = 4.4 nM and ES = 0 nM)
AuNP-Hep for enhanced microdialysis sampling
restrictions on pharmacy manufacturing facilities mean that
formulation with this blood product is either not allowed or
else prohibitively expensive. This presents a significant logis-
tical barrier to microdialysis sampling of proteins. Synthetic
alternatives, such as AuNP-Hep, are therefore a feasible
means of overcoming this barrier.
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